Amgen INC 8-K filings

Amgen announced robust second quarter 2026 financial results, with total revenues climbing 10% year-over-year to $10.1 billion, driven by strong product sales growth.

Amgen Inc. disclosed a material cybersecurity incident involving unauthorized access and exfiltration of data from third-party cloud environments, though it currently assesses no material impact on financial condition or operations.

Amgen shareholders re-elected all 12 director nominees and ratified the appointment of Ernst & Young LLP at the 2026 Annual Meeting.

Amgen Inc. announced the retirement of CFO Peter Griffith, effective August 31, 2026, and the appointment of Thomas Dittrich as his successor.

Amgen announced the retirement of its Executive Vice President and Chief Technology Officer, David M. Reese, effective June 30, 2026, with responsibilities to be redistributed and organizational changes implemented.

Amgen Inc. successfully completed the issuance of $4 billion in senior unsecured notes with maturities ranging from 2031 to 2056.

Amgen announced robust double-digit revenue and EPS growth for 2025, while providing 2026 guidance and detailing pipeline advancements and competitive challenges.

Amgen Inc. announced the termination of its License and Collaboration Agreement with Kyowa Kirin Co., Ltd. for the drug rocatinlimab, transferring all development and commercialization responsibilities to Kyowa Kirin.

Amgen reported a 12% increase in total revenues to $9.6 billion for the third quarter of 2025, driven by robust volume growth across key products and significant pipeline advancements.

Amgen reported robust second quarter 2025 financial results, with total revenues up 9% to $9.2 billion and GAAP EPS increasing 92% to $2.65, driven by strong product volume growth and pipeline advancements.

Amgen Inc. announced the successful election of all 12 director nominees, the approval of executive compensation, and the ratification of Ernst & Young LLP as its independent auditor at its Annual Meeting held on May 23, 2025.

Amgen's first quarter 2025 results show a 9% increase in total revenues, driven by strong product sales and volume growth.

Amgen's Q4 and full year 2024 results showcase robust revenue growth driven by volume increases and the acquisition of Horizon Therapeutics, despite a decrease in GAAP EPS due to mark-to-market losses and higher operating expenses.

Amgen's third quarter 2024 results show a significant increase in revenue and earnings, driven by strong volume growth and the acquisition of Horizon Therapeutics.

Amgen's second quarter 2024 results show a 20% increase in total revenue to $8.4 billion, fueled by strong volume growth and the acquisition of Horizon Therapeutics.

Amgen's stockholders approved an amended equity incentive plan and elected all director nominees at the company's 2024 annual meeting.

Amgen's first quarter 2024 results show a 22% revenue increase to $7.4 billion, driven by strong volume growth and the acquisition of Horizon Therapeutics.

Amgen's fourth quarter and full year 2023 results show significant revenue growth, driven by volume increases and the acquisition of Horizon Therapeutics.